9 results about "Growth factor receptor" patented technology

The present application belongs to the field of biomedical technology, and particularly relates to an axial length and growth trend evaluation method of eye axis based on PDGFRA gene and a PDGFRA enzyme activity control agent. The method comprises the following steps: 1) collecting an eye biological sample of a subject; 2) based on the expression level of PDGFRA gene of platelet-derived growth factor receptor alpha in the collected biological sample; 3) based on the expression level, calculating the axial length of the eye axis according to the quantitative relationship between the expression amount of PDGFRA and the axial length of the eye axis, and predicting the growth trend of the axial length of the eye axis through additional calculation. The technical scheme of the present application can effectively detect and evaluate the axial length of the eye axis, effectively judge the growth trend of the axial length of the eye axis, and directly and efficiently control the axial length of the eye axis and its growth trend through the existing drug components.

Modified natural killer (NK) cells or T cells expressing hematopoietic growth factor receptors are provided. In some aspects, the modified NK cells or T cells express thrombopoietin receptors, erythropoietin receptors, or chimeric peptides comprising an extracellular domain, a transmembrane domain, and an intracellular domain including an intracellular signaling domain of an interleukin receptor. Methods for treating cancer subjects are also provided, comprising administering modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or an erythropoietin receptor agonist, and in some instances, in combination with interleukin-2, particularly reduced or low doses of IL-2.

The present invention relates to a polynucleotide molecule comprising a nucleotide sequence encoding a chimeric antigen receptor (CAR) or fragment thereof, said chimeric antigen receptor (CAR) or fragment thereof i) comprising an extracellular domain comprising an antigen binding region that binds to epidermal growth factor receptor variant III (EGFRvIII); or ii) comprising an extracellular domain comprising an antigen binding region that binds to CD19; wherein the nucleotide sequence encoding the CAR is operably linked to a promoter, and wherein the polynucleotide molecule further comprises a nucleotide sequence encoding a heterologous signal peptide fused to a signal regulatory protein gamma (SIRPy)-related protein (SGRP). The present invention further relates to a chimeric antigen receptor (CAR)-T cell expressing the polynucleotide molecule, as well as a method of treating cancer using said polynucleotide molecule and / or a chimeric antigen receptor (CAR)-T cell expressing said polynucleotide molecule.

This disclosure relates to an Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) and an anti-EGFR / cMET antibody molecule for use in combination in the treatment of cancer (for example, non-small cell lung cancer [NSCLC]).

The present invention relates to a compound capable of preventing or treating lung cancer by inhibiting the expression or activity of Anoctamin 1 (ANO1), which is a calcium-activated chloride channel, and epidermal growth factor receptor (EGFR), which is an epithelial growth factor receptor. The compound of the present invention can be advantageously used alone as a composition for preventing or treating lung cancer, can be used per se as a dual-target anticancer drug for ANO1 and EGFR, and can also be used as an adjuvant or a combination preparation in combination with an EGFR-targeted therapeutic agent.

The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full-length antibody. In some aspects, the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some aspects, the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.

Provided herein are methods of engineering a cell line for reduced dependence on exogenous growth factor(s). In some embodiments, the method includes introducing into a cell one or more of: a polynucleotide comprising a coding sequence of a growth factor ligand; a polynucleotide comprising a coding sequence of a growth factor receptor; or a polynucleotide comprising a coding sequence of an activated downstream growth factor target, and culturing the cells in a cultivation infrastructure.

Disclosed herein are compounds useful for the inhibition of insulin-like growth factor 1 receptor (IGF-1R). The compounds have a general Formula (I): or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, thyroid-associated ophthalmopathy, Graves' opthalmopathy or Graves' orbitopathy. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).